Amalia M. Issa

ORCID: 0000-0002-1667-3280
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pharmacogenetics and Drug Metabolism
  • BRCA gene mutations in cancer
  • Health Systems, Economic Evaluations, Quality of Life
  • Genomics and Rare Diseases
  • Fatty Acid Research and Health
  • Ethics in Clinical Research
  • Pharmaceutical studies and practices
  • Cancer Genomics and Diagnostics
  • Computational Drug Discovery Methods
  • Statistical Methods in Clinical Trials
  • Genetic factors in colorectal cancer
  • Pharmaceutical Economics and Policy
  • Patient-Provider Communication in Healthcare
  • Colorectal Cancer Treatments and Studies
  • Health and Medical Research Impacts
  • Cancer, Lipids, and Metabolism
  • Neuroscience and Neuropharmacology Research
  • Genetics, Bioinformatics, and Biomedical Research
  • Biosimilars and Bioanalytical Methods
  • Breast Cancer Treatment Studies
  • Colorectal Cancer Screening and Detection
  • Gene expression and cancer classification
  • Artificial Intelligence in Healthcare and Education
  • Lipid metabolism and biosynthesis
  • Bacterial Infections and Vaccines

McGill University
1996-2024

Targeted Medical Pharma (United States)
2008-2024

University of the Sciences
2012-2022

McGill University Health Centre
2021

University of Houston
2006-2020

Target (United States)
2009-2018

McGill University and Génome Québec Innovation Centre
2018

Houston Methodist
2006-2013

Methodist Hospital
2006-2013

Methodist Hospital
2011

Abstract: The characteristic pathological features of the postmortem brain Alzheimer's disease (AD) patients include, among other features, presence neuritic plaques composed amyloid β‐peptide (Aβ) and loss basal forebrain cholinergic neurons, which innervate hippocampus cortex. Studies changes that characterize AD several lines evidence indicate Aβ accumulation in vivo may initiate and/or contribute to process neurodegeneration thereby development AD. However, mechanisms by peptide...

10.1046/j.1471-4159.1998.70052179.x article EN Journal of Neurochemistry 1998-05-01

Abstract BACKGROUND: Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph node‐negative, estrogen receptor‐positive, early stage breast cancer who are most likely benefit from adjuvant chemotherapy. The authors of this report evaluated the cost effectiveness recurrence score‐guided treatment using 2 commercially available GEP tests, Onco type DX (Genomic Health, Redwood City, Calif) and MammaPrint (Agendia Inc., Irvine, Calif), a...

10.1002/cncr.27443 article EN Cancer 2012-02-22

N/A

10.26443/mjm.v10i1.625 article EN cc-by-nc-sa McGill Journal of Medicine 2020-12-01

<i>Background/Aims:</i> Although pharmacogenomics-based diagnostics and therapeutics are increasingly being translated into personalized medicine applications, relatively little evidence exists about how novel technologies will be accepted adopted by patients. It is important to understand the characteristics of genomic targeted that might impact utilization or serve as barriers adoption these in order formulate appropriate policies procedures. The objective this study was...

10.1159/000189629 article EN Public Health Genomics 2009-01-01

Pharmacogenomics is gaining increasing importance in the therapeutics of cancer; yet, there little knowledge cancer patients' attitudes toward use pharmacogenomic testing clinical practice. We carried out this study to explore acceptance, understanding, and willingness-to-pay for testing.A broad cross-section gastrointestinal, lung, breast, other patients were interviewed terms their acceptance using hypothetical time, efficacy, toxicity trade-off scenarios.Among 96% 123 adjuvant accepting...

10.1097/fpc.0000000000000061 article EN Pharmacogenetics and Genomics 2014-06-06

AI-enabled digital twins (DTs) are advanced virtual models of a complex real-world system, augmented with predictive AI capabilities, which have potential for transforming healthcare and clincial decision making. Despite the growing interest need in such DTs, literature lacks unified framework its development implementation. This study aims to map existing knowledge on DTs clinical decision-making, develop comprehensive Informed by scoping review frameworks established Arksey O'Malley,...

10.1109/jbhi.2024.3521717 article EN IEEE Journal of Biomedical and Health Informatics 2024-01-01

Abstract Introduction: Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) plays a crucial role in regulating DNA damage repair. ATR inhibitors have shown promise against solid tumors, not only as monotherapies, but also combination with chemotherapy, radiotherapy, immunotherapy several clinical trials ongoing. The currently development low CNS-penetration are therefore sub-optimal for the treatment of brain tumors metastases. It has been proposed that could be used...

10.1158/1538-7445.am2025-2917 article EN Cancer Research 2025-04-21

<h3>Purpose:</h3> The purpose of this study was to implement a clinical pharmacist-led medication therapy management (MTM) service within primary-care setting that is enhanced by 1) decision support system (CDSS) includes unique combination risk mitigation factors, which aids the pharmacist in interpreting profile, and 2) pharmacogenomics (PGx) testing. <h3>Methods:</h3> This implementation study, whereby Medicare beneficiaries were eligible if they patients Elmwood Family Physicians,...

10.3122/jabfm.2017.06.170145 article EN The Journal of the American Board of Family Medicine 2017-11-01

Aim: Our aim was to assess the knowledge and attitudes of US hospital pharmacists about implementation clinical pharmacogenomics, examine liability risks adopting pharmacogenomics by pharmacists. Methods: We surveyed Linear regression models predictor variables for pharmacist adoption use were analyzed. Results: The survey administered 660 (23% response rate; n = 149). majority respondents (72%) favor implementing into pharmacy practice. However, only 25% are confident in their abilities...

10.2217/pme-2016-0063 article EN Personalized Medicine 2016-10-19

TUDIES SHOW THAT TISSUE LEVels of arachadonic acid-and eicosopentaenoic acid (EPA)derived eicosanoids influence many physiological processes, including calcium transport across cell membranes, angiogenesis, apoptosis, proliferation, and immune function. [1]2][3][4] These processes are integral to the system hence pathogenesis autoimmune diseases such as arthritis, systemic lupus erythematosus, asthma, well cancer.0][11][12][13][14][15][16][17][18][19][20][21][22] In addition, dietary omega-3...

10.1001/jama.295.16.1900-a article EN JAMA 2006-04-25

Primary care is recognized worldwide as a key component for improving health outcomes in the population. At same time, healthcare systems are rapidly changing with increasing expectations from technological advances. Genomics major driver how medicine being practiced; however, importance primary has been under-appreciated. Strategically implementing genomics way that accounts unique characteristics of context essential. In this perspective, we present important areas believe critical...

10.2217/pme.14.36 article EN Personalized Medicine 2014-07-01

Abstract: The biochemical mechanisms involved in the regulation of acetylcholine (ACh) turnover are poorly understood. In experiments reported here, we examined whether inhibition serine/threonine phosphatases 1 and 2A by calyculin A or okadaic acid alters ACh synthesis rat hippocampal preparations. With slices, (50 n M ) reduced significantly ( p &lt; 0.01) [ 3 H]ACh from H]choline. Both produced significant depletion endogenous tissue a concentration‐dependent manner 0.01). This was not...

10.1046/j.1471-4159.1996.66051924.x article EN Journal of Neurochemistry 1996-05-01

Several novel pharmacogenomic diagnostic tests are commercially available for breast and colorectal cancer, increasingly being used in clinical practice improving treatment decisions. However, there is little evidence evaluating the value of these new genomic technologies from perspective patients. As part an ongoing effort to understand continuum process adoption diagnostics, our aim this study was examine diagnostics cancer patients, their willingness adopt use diagnostics.We conducted six...

10.2217/pme.11.39 article EN Personalized Medicine 2011-07-01
Coming Soon ...